Bimekizumab Demonstrates Skin Clearance in Phase 2b Psoriasis Study with ...
(WorldNews Belgium)

Positive top line results from the UCB BE ABLE study The Phase 2b BE ABLE study met the primary objective of establishing dose response, with up to 79% of patients achieving at least 90% skin clearance in the psoriasis area and severity index (PASI90) at week 12 Up to 60% of patients achieved complete skin clearance at week 12 as measured by PASI100, a secondary efficacy variable Bimekizumab is a monoclonal antibody rationally designed to potently and selectively neutralize both IL-17A and IL-17F, two key pro-inflammatory cytokines involved in the pathophysiology of psoriasis The BE ABLE study provides the first Phase 2b results with this novel therapeutic approach, indicating that...